STEAP1 silencing reportedly inhibited the activity and proliferation of LNCaP cells and induced apoptosis in prostate cancer by affecting p53, p21, Bax, Bax/Bcl-2, Caspase-9, FasL, Caspase-8, and Caspase-3 (Gomes et al., 2018). Here, BCL2 is linked to prostate carcinoma.